Dupixent AD, INN dupilumab Enhertu low HER2, INN trastuzumab deruxtecan Kyprolis MM, INN carfilzomib Lynparza early breast cancer, INN olaparib Nubeqa mHSPC, INN darolutamide Ofev PF-ILD, INN nintedanib
